Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores

Tracy, Chad R.; Flynn, Kevin J.; Sjoberg, Daniel D.; Gellhaus, Paul T.; Metz, Catherine M.; Ehdaie, Behfar

doi:10.1016/j.urolonc.2020.09.019

Cited by 12 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of csPCa increased from 26% to 44% for the first core to the third core, and from 44% to 52% from the third to the fifth core. However, that study only included lesions with PI-RADS score of 4 or 5, and excluded PI-RADS score 3 lesions in the reported results [26]. PI-RADS score 3 lesions were reported separately and had much lower frequencies of upgrading with sequential cores, similar to the findings in the present study.…”

Section: Accepted Manuscriptsupporting

confidence: 80%

“…Prior studies examined the diagnostic value of increasing cores in MRGB [8,17,[21][22][23][24]26,27]. A study from 2016 demonstrated an increase in csPCa diagnosis with in-gantry MRGB when increasing from 1 to 2 cores [27], however did not assess the impact on prostate cancer diagnosis when increasing from 2 to 3 cores.…”

Section: Discussionmentioning

confidence: 99%

“…A 2016 consensus statement recommended that at least two cores be obtained per lesion during MRGB [20]. Prior studies evaluated the value of obtaining varying numbers of cores in MRGB [8,17,[21][22][23][24][25]26], although a paucity of studies have examined the value of obtaining more than 2 cores for in-gantry MRGB [27,26].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…The discrepancy in upgrade frequency between the earlier and current study is likely due to a difference in threshold for csPCa (Gleason score 4+3 in the previous study vs Gleason score 3+4 in the present study). A separate prospective study from 2020 sought to determine the optimal number of cores to obtain with in-gantry MRGB [26]. Five cores were obtained per lesion, and rates of csPCa (ISUP-GG ≥ 2) were evaluated for the first, third, and fifth cores.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…The study sample was heterogenous, with only 7.0% of patients undergoing their first prostate biopsy, thereby limiting generalizability to such patients. Although MRGB is currently recommended after a negative prostate biopsy [26], interest in implementing MRGB in biopsy-naïve patients is growing [39].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 4 more Smart Citations

Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy

Seyfried¹,

Mahran

Obmann

et al. 2021

American Journal of Roentgenology

View full text Add to dashboard Cite

Section: Accepted Manuscriptsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy

Seyfried¹,

Mahran

Obmann

et al. 2021

American Journal of Roentgenology

View full text Add to dashboard Cite

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores

et al. 2021

View full text Add to dashboard Cite

Background: Recently, an increase in the rates of high-risk prostate cancer (PCa) was reported. We tested whether the rates of and low, intermediate, high and very high-risk PCa changed over time. We also tested whether the number of prostate biopsy cores contributed to changes rates over time.Methods: Within the Surveillance, Epidemiology and End Results (SEER) database (2010)(2011)(2012)(2013)(2014)(2015), annual rates of low, intermediate, high-risk according to traditional National Comprehensive Cancer Network (NCCN) and high versus very high-risk PCa according to Johns Hopkins classification were tabulated without and with adjustment for the number of prostate biopsy cores.Results: In 119,574 eligible prostate cancer patients, the rates of NCCN low, intermediate, and high-risk PCa were, respectively, 29.7%, 47.8%, and 22.5%. Of high-risk patients, 39.6% and 60.4% fulfilled high and very high-risk criteria. Without adjustment for number of prostate biopsy cores, the estimated annual percentage changes (EAPC) for low, intermediate, high and very high-risk were respectively −5.5% (32.4%-24.9%, p < .01), +0.5% (47.6%-48.4%, p = .09), +4.1% (8.2%-9.9%, p < .01), and +8.9% (11.8%-16.9%, p < .01), between 2010 and 2015. After adjustment for number of prostate biopsy cores, differences in rates over time disappeared and ranged from 29.8%-29.7% for low risk, 47.9%-47.9% for intermediate risk, 8.9%-9.0% for high-risk, and 13.6%-13.6% for very high-risk PCa (all p > .05). Conclusions:The rates of high and very high-risk PCa are strongly associated with the number of prostate biopsy cores, that in turn may be driven by broader use magnetic resonance imaging (MRI).

show abstract

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of core number and location

et al. 2023

View full text Add to dashboard Cite

Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores

Cited by 12 publications

References 22 publications

Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy

Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of core number and location

Contact Info

Product

Resources

About